Servier pays for rights for microRNA candidates from MiRagen


Paris/Boulder – French drugmaker Servier has secured the rights for two miroRNA drug candidates from US-biotech MiRagen. Both companies clinched a partnership agreement under which Servier would fund the research, development and commercialisation of two of the most promising candidates to treat cardiovascular disease, miR-208 and miR-15/195, as well as one yet-to-be-determined discovery target. In exchange for commercialisation rights outside the U.S. and Japan, miRagen gets US$45 million in an upfront payment, research support and near-term milestones, up to US$352 million in total milestones and double-digit royalties on approved products. It's a "transformational deal" for the fledgling MiRagen, a company that has raised US$18 million in venture capital since its 2007 founding, said CEO William Marshall. The deal is also welcome news to Atlas Venture and Boulder Ventures, which helped launch miRagen with an US$8 million Series A back in 2008. "It's always been a question of 'How do we get (the large-scale trials)?'" Marshall said. "Now we've got a clear path to that." Inhibiting microRNA-208 could increase resistance to cardiac stress, while the inhibition of miR-15/195 not only reduces the amount of cells that die after a heart attack, but also shows promise in helping the regeneration of cells.



Stockholm/Suresnes - Swedish BioInvent International AB and French Laboratoires Servier are working together on an oncology target. Under the terms of the agreement, Servier will engage BioInvent to screen its proprietary library...



Romainville – Cellectis SA has completed its acquisition of Cellartis AB, which provides stem cell-based in vitro R&D tools, in a cash and stock deal valued at €29.1m (US$39.9m). Cellartis shareholders received 1.9 million...



Paris – One of the biggest European biotech deals of 2011 is now sealed. As announced in September, the shareholders of French genome engineering specialist Cellectis approved the takeover of Swedish Cellartis, the European...



Paris - Sanofi and MS patients can breathe a sigh of relief. At an MS congress in Amsterdam, the company presented impressive results of a phase III trial comparing alemtuzumab with subcutaneous Rebif interferon beta-1a in 581...



Paris/Hyderabad – Sanofi Aventis believes in India. The pharmaceutical company announced the opening a state-of-the-art vaccine manufacturing facility, believed to be Asia's biggest, in March 2012. In the coming years Sanofi will...



Paris – Nanobiotix S.A. is entering the clinical stage with its NanoXray nano­particle therapy, which aims to increase the efficacy of radiotherapy without increasing dosage. In mid-September, the French nano­medicine company...

Sweden, FranceFrance


Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62...

Germany, FranceFrance


Luxembourg - Disorientation reigns in green biotechnology in Europe. Two decisions by the European Court of Justice regarding genetically modified crops point in different directions. On Thursday the judges left the opponents of...

Displaying results 11 to 20 out of 268

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Stock list

All quotes







              No liability assumed, Date: 05.07.2015

              Current issue

              All issues